Keenan A Walker1, B Gwen Windham2, Charles H Brown3, David S Knopman4, Clifford R Jack5, Thomas H Mosley2, Elizabeth Selvin6, Dean F Wong7, Timothy M Hughes8, Yun Zhou7, Alden L Gross6, Rebecca F Gottesman1,6. 1. Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 2. Department of Medicine, Division of Geriatrics, University of Mississippi Medical Center, Jackson, MS, USA. 3. Department of Anesthesiology and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA. 4. Department of Neurology, Mayo Clinic, Rochester, MN, USA. 5. Department of Radiology, Mayo Clinic, Rochester, MN, USA. 6. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 7. Department of Radiology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 8. Department of Internal Medicine, Section on Gerontology and Geriatrics Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Abstract
BACKGROUND: Although inflammation has been implicated in the pathogenesis of Alzheimer's disease, the effects of systemic inflammation on brain amyloid deposition remain unclear. OBJECTIVE: We examined the association of midlife and late-life systemic inflammation with late-life brain amyloid levels in a community sample of non-demented older adults from the Atherosclerosis Risk in Communities (ARIC) - PET Study. METHODS: 339 non-demented participants (age: 75 [SD 5]) were recruited from the ARIC Study to undergo florbetapir PET (amyloid) imaging. Blood levels of high sensitivity C-reactive protein (CRP), a marker of systemic inflammation, were measured 22 years (Visit 2), 16 years (Visit 4), and up to 2 years before PET imaging (Visit 5). Elevated brain amyloid deposition (standardized uptake value ratio >1.2) was the primary outcome. RESULTS: Our primary analyses found no association of midlife and late-life CRP with late-life brain amyloid levels. However, in secondary stratified analyses, we found that higher midlife (Visit 2) CRP was associated with elevated amyloid among males (OR 1.65, 95% CI: 1.13-2.42), and among white (OR 1.33, 95% CI: 1.02-1.75), but not African American, participants (p-interactions<0.05). Among male participants, those who maintained high CRP levels (≥3 mg/L) throughout mid- and late-life were most likely to have elevated brain amyloid (OR, 8.81; 95% CI: 1.23, 62.91). CONCLUSIONS: Although our primary analysis does not support an association between systemic inflammation and brain amyloid deposition, we found evidence for sex- and race-dependent associations. However, findings from subgroup analyses should be interpreted with caution.
BACKGROUND: Although inflammation has been implicated in the pathogenesis of Alzheimer's disease, the effects of systemic inflammation on brain amyloid deposition remain unclear. OBJECTIVE: We examined the association of midlife and late-life systemic inflammation with late-life brain amyloid levels in a community sample of non-demented older adults from the Atherosclerosis Risk in Communities (ARIC) - PET Study. METHODS: 339 non-demented participants (age: 75 [SD 5]) were recruited from the ARIC Study to undergo florbetapir PET (amyloid) imaging. Blood levels of high sensitivity C-reactive protein (CRP), a marker of systemic inflammation, were measured 22 years (Visit 2), 16 years (Visit 4), and up to 2 years before PET imaging (Visit 5). Elevated brain amyloid deposition (standardized uptake value ratio >1.2) was the primary outcome. RESULTS: Our primary analyses found no association of midlife and late-life CRP with late-life brain amyloid levels. However, in secondary stratified analyses, we found that higher midlife (Visit 2) CRP was associated with elevated amyloid among males (OR 1.65, 95% CI: 1.13-2.42), and among white (OR 1.33, 95% CI: 1.02-1.75), but not African American, participants (p-interactions<0.05). Among male participants, those who maintained high CRP levels (≥3 mg/L) throughout mid- and late-life were most likely to have elevated brain amyloid (OR, 8.81; 95% CI: 1.23, 62.91). CONCLUSIONS: Although our primary analysis does not support an association between systemic inflammation and brain amyloid deposition, we found evidence for sex- and race-dependent associations. However, findings from subgroup analyses should be interpreted with caution.
Authors: Martha Clare Morris; Paul A Scherr; Liesi E Hebert; David A Bennett; Robert S Wilson; Robert J Glynn; Denis A Evans Journal: Neuroepidemiology Date: 2002 May-Jun Impact factor: 3.282
Authors: V R Varma; S Varma; Y An; T J Hohman; S Seddighi; R Casanova; A Beri; E B Dammer; N T Seyfried; O Pletnikova; A Moghekar; M R Wilson; J J Lah; R J O'Brien; A I Levey; J C Troncoso; M S Albert; M Thambisetty Journal: Mol Psychiatry Date: 2016-11-22 Impact factor: 15.992
Authors: Emil M DeGoma; Benjamin French; Richard L Dunbar; Matthew A Allison; Emile R Mohler; Matthew J Budoff Journal: Atherosclerosis Date: 2012-07-20 Impact factor: 5.162
Authors: Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters Journal: Lancet Neurol Date: 2013-03-08 Impact factor: 44.182
Authors: Jin G Sheng; Susan H Bora; G Xu; David R Borchelt; Donald L Price; Vassilis E Koliatsos Journal: Neurobiol Dis Date: 2003-10 Impact factor: 5.996
Authors: Stephanos Kyrkanides; Ross H Tallents; Jen-Nie H Miller; Mallory E Olschowka; Renee Johnson; Meixiang Yang; John A Olschowka; Sabine M Brouxhon; M Kerry O'Banion Journal: J Neuroinflammation Date: 2011-09-07 Impact factor: 8.322
Authors: Keenan A Walker; Sahil Chawla; Carlos Nogueras-Ortiz; Josef Coresh; A Richey Sharrett; Dean F Wong; Clifford R Jack; Anthony J Spychalla; Rebecca F Gottesman; Dimitrios Kapogiannis Journal: Neurobiol Aging Date: 2020-10-01 Impact factor: 4.673
Authors: Aaron J Cohen; Kanako Teramoto; Brian Claggett; Leo Buckley; Scott Solomon; Christie Ballantyne; Elizabeth Selvin; Amil M Shah Journal: J Card Fail Date: 2021-07-25 Impact factor: 5.712
Authors: Lauren E Oberlin; Kirk I Erickson; Rachel Mackey; William E Klunk; Howard Aizenstein; Brian J Lopresti; Lewis H Kuller; Oscar L Lopez; Beth E Snitz Journal: Brain Behav Immun Date: 2021-03-15 Impact factor: 19.227
Authors: Chris Oliver; Dawn Adams; Anthony J Holland; Stephanie S G Brown; Sarah Ball; Karen Dodd; Janet Carr Journal: Int J Geriatr Psychiatry Date: 2021-12-24 Impact factor: 3.850
Authors: Stan G Louie; Hussein N Yassine; Brandon Ebright; Isaac Assante; Roy A Poblete; Shaowei Wang; Marlon V Duro; David A Bennett; Zoe Arvanitakis Journal: Alzheimers Res Ther Date: 2022-10-11 Impact factor: 8.823
Authors: Keenan A Walker; Rebecca F Gottesman; Josef Coresh; A Richey Sharrett; David S Knopman; Thomas H Mosley; Alvaro Alonso; Yun Zhou; Dean F Wong; Charles H Brown Journal: Anesthesiology Date: 2020-06 Impact factor: 7.892